Cardinal Health, Inc. (CAH): A Bull Case Theory

Jirsak/Shutterstock.com

Cardinal Health, Inc. operates arsenic a healthcare services and products institution successful the United States and internationally. CAH continues to show resilience and dependable maturation wrong the healthcare sector, driven by beardown request and operational efficiency. The institution operates done 2 main divisions: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution.

Its Pharmaceutical and Specialty Solutions conception delivers tailored solutions to hospitals, healthcare systems, pharmacies, ambulatory surgery centers, objective laboratories, doc offices, and patients astatine home, distributing branded and generic pharmaceuticals, specialty drugs, and over-the-counter healthcare products.

Meanwhile, the Global Medical Products and Distribution part supports pharmaceutical manufacturers and healthcare providers with specialty pharmaceutical services, pharmacy absorption for hospitals, assemblage health center pharmacies, and repackaging of generic and over-the-counter products.

In its latest quarter, CAH reported gross of $64 billion, a 22.4% summation from $52.3 cardinal a twelvemonth ago, alongside operating net of $611 million, oregon $2.55 per share, up 35.6% from $460 million, oregon $1.88 per share. These results importantly exceeded expert expectations of $58.6 cardinal successful gross and $2.21 per stock successful earnings, representing an 8.4% gross astonishment and a 15.4% net beat.

Positive expert sentiment has besides increased, with statement net estimates rising 4.3% implicit the past 3 months, signaling potential for continued upside. With disciplined execution, a antiaircraft presumption successful healthcare, and beardown operational performance, Cardinal Health presents a compelling concern opportunity. The operation of robust gross growth, important net outperformance, and favorable analyst revisions reinforces the lawsuit for CAH arsenic a buy, offering some stableness and imaginable upside successful the healthcare services space.

Previously, we covered a bullish thesis on Thermo Fisher Scientific Inc. (TMO) by Kontra successful October 2024, which highlighted its starring presumption successful beingness sciences tools, diversified segments, and prime compounding potential. TMO’s banal terms has depreciated by 14.62% since our coverage. @MoneyShow shares a akin presumption but emphasizes Cardinal Health, Inc.’s (CAH) antiaircraft positioning, operational efficiency, and beardown gross and net growth, highlighting steady, resilient show successful healthcare services.